North West Labs, INC.

North West Labs, INC. was paid $10.93M by Medicaid between Jan 2018 and Dec 2024, across 90 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 53% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Michigan

Rank by total paid#11 of 108

Median peer was paid$588K

This provider vs. median19×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	1,826	$80K
2019	3,161	$251K
2020	22,357	$1.36M
2021	91,051	$4.77M
2022	46,639	$2.46M
2023	21,638	$1.02M
2024incomplete	43,102	$974K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	53%	90,921	83,274	$5.83M
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	20%	19,099	17,890	$2.19M
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	8.1%	49,104	44,997	$885K
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	5.8%	10,045	5,444	$634K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	5.5%	16,430	13,783	$603K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	2.8%	10,907	8,699	$305K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	2.5%	5,963	4,071	$269K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	1,607	1,566	$43K
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	<1%	1,233	1,211	$37K
87804	Infectious agent antigen detection by immunoassay; Influenza, each type	<1%	4,702	2,401	$33K
81514		<1%	259	256	$12K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	1,224	1,221	$8K

78 more codes

87634		<1%	551	$8K
87807		<1%	1,261	$8K
84443	Thyroid stimulating hormone (TSH)	<1%	1,489	$7K
82652		<1%	724	$6K
80061	Lipid panel	<1%	1,468	$6K
80053	Comprehensive metabolic panel	<1%	1,769	$5K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	321	$4K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	1,855	$4K
83036	Hemoglobin; glycosylated (A1C)	<1%	1,399	$4K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	303	$4K
86409		<1%	80	$4K
82607		<1%	1,113	$4K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	284	$3K
86408		<1%	112	$3K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	295	$3K
84439		<1%	845	$2K
86803		<1%	217	$1K
88175	Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer	<1%	124	$837.14
82728		<1%	284	$835.46
82746		<1%	213	$766.46
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	<1%	15	$732.41
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	<1%	74	$610.05
84481		<1%	136	$583.50
84153		<1%	127	$549.09
83735		<1%	339	$537.54
87086	Culture, bacterial; quantitative colony count, urine	<1%	172	$438.16
83550		<1%	254	$434.40
81001		<1%	400	$301.65
85027		<1%	144	$268.68
87420		<1%	23	$188.96
84480		<1%	69	$187.84
84436		<1%	126	$182.08
86592		<1%	73	$148.26
80069		<1%	59	$136.61
83540		<1%	66	$134.02
84479		<1%	56	$133.75
83690		<1%	76	$133.38
84100		<1%	82	$110.20
82150		<1%	71	$106.16
80171		<1%	18	$104.86
80048	Basic metabolic panel (calcium, ionized)	<1%	41	$98.74
83992		<1%	18	$92.33
82248		<1%	69	$79.07
86706		<1%	12	$71.20
84154		<1%	12	$60.92
86140		<1%	42	$51.71
82043		<1%	35	$43.66
82570		<1%	28	$38.48
80164		<1%	14	$33.63
80076		<1%	75	$27.04
83721		<1%	17	$25.26
83986		<1%	17	$16.52
85652		<1%	14	$6.72
81003		<1%	16	$6.60
86702		<1%	218	$5.48
86701		<1%	218	$3.60
80358		0%	15	$0.00
80363		0%	15	$0.00
80367		0%	16	$0.00
80353		0%	16	$0.00
80349		0%	16	$0.00
80345		0%	16	$0.00
80324		0%	16	$0.00
80359		0%	16	$0.00
80372		0%	16	$0.00
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	0%	15	$0.00
80356		0%	16	$0.00
80366		0%	16	$0.00
80332		0%	15	$0.00
80336		0%	15	$0.00
80360		0%	16	$0.00
80348		0%	16	$0.00
80365		0%	16	$0.00
80370		0%	16	$0.00
80361		0%	16	$0.00
80346		0%	16	$0.00
80354		0%	16	$0.00
80373		0%	16	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialELIAS, OMAR (PRESIDENT)